View live charts, options flow & technicals for Perrigo Company plc →
Open Dashboard
Perrigo Company plc (PRGO) is a healthcare company in the drug manufacturers - specialty & generic industry with $4.14B in trailing revenue — analyst consensus: none.
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Key Statistics
Market Cap
$2.13B
Revenue (TTM)
$4.14B
EPS (TTM)
$-12.29
EPS (Fwd est.)
$2.40
Employees
8,100
Forward P/E
6.43
PEG Ratio
1.14
Price / Sales
0.51
Price / Book
0.85
EV / EBITDA
8.47
Beta (5Y)
0.60
Analyst Consensus
Consensus
None
Analyst Price Target
+7.0% upside
Target: $16.50
Annual Revenue & Net Income
RevenueNet Income
'22
$4.45B
$-140.00M
'23
$4.66B
$-10.00M
'24
$4.37B
$-170.00M
'25
$4.25B
$-1.43B
Earnings History
Quarter
Actual EPS
Estimate
Result
Aug 2026
$0.50
$0.36
Beat (+40.9%)
May 2026
$0.43
$0.31
Beat (+40.2%)
Feb 2026
$0.77
$0.78
Miss (-1.3%)
Nov 2025
$0.80
$0.77
Beat (+3.9%)
Next Earnings Report
Perrigo Company plc is next expected to report earnings on 04 Nov 2026.
Profitability
33.3%
3.8%
-41.9%
Gross MarginOperating MarginNet Margin
Revenue Growth (YoY)
-3.2%
Return on Equity
-48.7%
Return on Assets
2.0%
Balance Sheet
Cash & Equivalents
$400.00M
Total Debt
$3.48B
Net Position
$3.08B (net debt)
Free Cash Flow (TTM)
$440.00M
Debt / Equity
138.18
Share Ownership
Institutions 114.7%
Insiders 0.4%
Institutional figure exceeds 100% due to short selling
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral…
What is PRGO's market cap?
Perrigo Company plc has a market capitalization of approximately $2.13B.
How much revenue does PRGO generate?
Perrigo Company plc generated $4.14B in trailing 12-month revenue.
What do analysts say about PRGO?
The analyst consensus rating for Perrigo Company plc is none, with a mean price target of $16.50. That implies +7.0% upside from the current price.
When does PRGO report earnings?
Perrigo Company plc is next scheduled to report earnings on 04 Nov 2026.
Does PRGO pay a dividend?
Yes. Perrigo Company plc pays a dividend with a current yield of 7.52%, at an annual rate of $1.16 per share.
View live charts, options flow, gamma exposure, earnings history, and technical analysis for Perrigo Company plc on Apsis Markets.